141 related articles for article (PubMed ID: 15708355)
1. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation.
Planavila A; Laguna JC; Vázquez-Carrera M
Biochim Biophys Acta; 2005 Feb; 1687(1-3):76-83. PubMed ID: 15708355
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells.
Planavila A; Sánchez RM; Merlos M; Laguna JC; Vázquez-Carrera M
Biochim Biophys Acta; 2005 Sep; 1736(2):120-7. PubMed ID: 16139565
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes.
Planavila A; Rodríguez-Calvo R; Jové M; Michalik L; Wahli W; Laguna JC; Vázquez-Carrera M
Cardiovasc Res; 2005 Mar; 65(4):832-41. PubMed ID: 15721863
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy.
Planavila A; Laguna JC; Vázquez-Carrera M
J Biol Chem; 2005 Apr; 280(17):17464-71. PubMed ID: 15728586
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptors and the control of fatty acid oxidation in cardiac hypertrophy.
Planavila A; Calvo RR; Vázquez-Carrera M
Mini Rev Med Chem; 2006 Mar; 6(3):357-63. PubMed ID: 16515475
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli.
Planavila A; Rodríguez-Calvo R; Palomer X; Coll T; Sánchez RM; Merlos M; Laguna JC; Vázquez-Carrera M
Biochim Biophys Acta; 2008; 1781(1-2):26-35. PubMed ID: 18036354
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Bustos C; Hernández-Presa MA; Ortego M; Tuñón J; Ortega L; Pérez F; Díaz C; Hernández G; Egido J
J Am Coll Cardiol; 1998 Dec; 32(7):2057-64. PubMed ID: 9857893
[TBL] [Abstract][Full Text] [Related]
8. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Lu JC; Cui W; Zhang HL; Liu F; Han M; Liu DM; Yin HN; Zhang K; Du J
Clin Exp Pharmacol Physiol; 2009 Nov; 36(11):1110-9. PubMed ID: 19413592
[TBL] [Abstract][Full Text] [Related]
9. [Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro].
Sheng L; Ye P; Liu YX
Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Dec; 33(12):1080-4. PubMed ID: 16563274
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.
Ye P; Sheng L; Zhang C; Liu Y
J Pharm Pharm Sci; 2006; 9(3):365-75. PubMed ID: 17207419
[TBL] [Abstract][Full Text] [Related]
11. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Bays HE; Schwartz S; Littlejohn T; Kerzner B; Krauss RM; Karpf DB; Choi YJ; Wang X; Naim S; Roberts BK
J Clin Endocrinol Metab; 2011 Sep; 96(9):2889-97. PubMed ID: 21752880
[TBL] [Abstract][Full Text] [Related]
12. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.
Ogata T; Miyauchi T; Sakai S; Takanashi M; Irukayama-Tomobe Y; Yamaguchi I
J Am Coll Cardiol; 2004 Apr; 43(8):1481-8. PubMed ID: 15093887
[TBL] [Abstract][Full Text] [Related]
13. Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase-2 and 9 in rats.
Cheng G; Xu G; Cai HW; Wang HH; Bao XF
Acta Pharmacol Sin; 2007 Apr; 28(4):511-7. PubMed ID: 17376290
[TBL] [Abstract][Full Text] [Related]
14. Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway.
Yang J; Huang C; Yang J; Jiang H; Ding J
Mol Cell Biochem; 2010 Dec; 345(1-2):189-95. PubMed ID: 20714791
[TBL] [Abstract][Full Text] [Related]
15. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Kleemann R; Verschuren L; de Rooij BJ; Lindeman J; de Maat MM; Szalai AJ; Princen HM; Kooistra T
Blood; 2004 Jun; 103(11):4188-94. PubMed ID: 14976045
[TBL] [Abstract][Full Text] [Related]
16. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Zou J; Le K; Xu S; Chen J; Liu Z; Chao X; Geng B; Luo J; Zeng S; Ye J; Liu P
Mol Cell Endocrinol; 2013 May; 370(1-2):103-12. PubMed ID: 23518069
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine.
Yin Z; Fang Y; Ren L; Wang X; Zhang A; Lin J; Li X
Neurosci Lett; 2009 Nov; 465(1):61-5. PubMed ID: 19733216
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Liao Y; Zhao H; Ogai A; Kato H; Asakura M; Kim J; Asanuma H; Minamino T; Takashima S; Kitakaze M
Hypertens Res; 2008 Feb; 31(2):335-44. PubMed ID: 18360054
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
20. Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Vilà L; Rebollo A; Ađalsteisson GS; Alegret M; Merlos M; Roglans N; Laguna JC
Toxicol Appl Pharmacol; 2011 Feb; 251(1):32-40. PubMed ID: 21122807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
